# Synnovation Therapeutics

Source: https://onco.cc/companies/synnovation-therapeutics/  
OnCo record `synnovation-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Synnovation Therapeutics develops targeted pills for genetically defined cancers. Its PARP1 blocker SNV1521, built to reach the brain, is in early trials including one with a RAS drug in pancreatic cancer; in 2026 Novartis agreed to buy its breast cancer PI3K-alpha programme for USD 2 billion upfront.

## Summary

Synnovation Therapeutics, with its main office in Wilmington, Delaware, launched on 24 January 2024 with a USD 102 million Series A led by Third Rock Ventures with Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management, to advance small-molecule precision oncology medicines. SNV1521 is a PARP1-selective, brain-penetrant inhibitor; its first patient was dosed on 11 March 2024, phase 1 data were presented at ESMO 2025, and a clinical collaboration with DualityBio on the HER3 antibody-drug conjugate DB-1310 was announced in October 2025. A further phase 1 study combines SNV1521 with the RAS(ON) inhibitor daraxonrasib in advanced pancreatic cancer. SNV4818, a pan-mutant-selective PI3Kα inhibitor, dosed its first patient on 24 February 2025; on 20 March 2026 Novartis agreed to acquire Pikavation Therapeutics, the wholly owned subsidiary holding the PI3Kα programmes, for USD 2 billion upfront and up to USD 1 billion in milestones, with Synnovation keeping SNV1521 and its other subsidiaries. Wenqing Yao is founder and chief executive and Liangxing Wu is co-founder.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Wilmington, DE
- Type: biotech
- Website: https://www.synnovationtx.com/

## Notes

- Founding year not stated. The SNV1521 trials are registered to ParVation Therapeutics, Inc. and the SNV4818 trial to Pikavation Therapeutics, Inc.; Pikavation is named by Synnovation as its subsidiary, while ParVation's relationship is inferred from the synnovationtx.com contact address on the registry entry and was not confirmed on a company page. Whether the Novartis acquisition of Pikavation had closed was not confirmed. The ESMO 2025 response figures were not read on a primary page and are not repeated.

## Sources

- Official website: https://www.synnovationtx.com/
- Launch and Series A release, January 2024: https://www.synnovationtx.com/news/synnovationtherapeuticslauncheswith102milliontoadvanceclinical-stagepipelineofprecision
- SNV1521 first patient dosed: https://www.synnovationtx.com/news/parp1-fip-pressrelease
- SNV4818 first patient dosed: https://www.synnovationtx.com/news/pi3ka-fip-pr
- Novartis to acquire the PI3K-alpha programme, March 2026: https://www.synnovationtx.com/news/novartis-to-acquire-synnovation-therapeutics-pan-mutant-selective-pi3ka-inhibitor-program

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/), [PI3K, AKT and mTOR inhibitors](https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/), [Synthetic lethality approaches](https://onco.cc/technologies/synthetic-lethality-approaches/)
- targets: [PARP](https://onco.cc/targets/parp/), [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/)
- drugs: [SNV1521](https://onco.cc/drugs/snv1521/)
- companies: [Cormorant Asset Management](https://onco.cc/companies/cormorant-asset-management/), [Novartis](https://onco.cc/companies/novartis/), [Third Rock Ventures](https://onco.cc/companies/third-rock-ventures/)
- trials: [First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer](https://onco.cc/trials/nct07756281/), [SNV1521 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06220864/), [SNV4818 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06736704/)

---
JSON: https://onco.cc/api/v1/entities/synnovation-therapeutics.json